When radiotherapy or chemotherapy of solid tumors was combined with the administration of a CXCR4 antagonist such as AMD3100, a significant decrease in primary tumor volume and reduced metastatic burden was observed [21–24]. This evidence concerns the gene CXCR4 and neoplasm.